AbbVie Inc.(ABBV)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for AbbVie Inc. (ABBV) over the last 3 months consists of 70 total transactions. Among these, company executives and board members conducted 70 buys (totaling 1,731,212 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 1,731,212 shares, reflecting net buying interest with an estimated net acquisitions value of $11.10M.
70 insider transactions found. Showing 10 of 70 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| DONOGHOE NICHOLAS | Officer | 32,710 | $8.18 | Aug 14, 2026 |
| FREYMAN THOMAS C | Director | 1,118 | $N/A | May 8, 2026 |
| FALK THOMAS J | Director | 1,118 | $N/A | May 8, 2026 |
| AUSTIN ROXANNE SCHUH | Director | 1,118 | $N/A | May 8, 2026 |
| WADDELL FREDERICK H | Director | 1,118 | $N/A | May 8, 2026 |
| RAPP EDWARD J | Director | 1,118 | $N/A | May 8, 2026 |
| HART BRETT J | Director | 1,118 | $N/A | May 8, 2026 |
| BURNSIDE WILLIAM H L | Director | 1,118 | $N/A | May 8, 2026 |
| MEYER MELODY B | Director | 1,118 | $N/A | May 8, 2026 |
| ROBERTS REBECCA B. | Director | 1,118 | $N/A | May 8, 2026 |
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.